cardiovascular diseases

News

Armed with positive results in two phase 3 trials, MSD is poised to be the first to file for approval of an oral PCSK9 drug to lower cholesterol.

News

George Medicines' Widaplik can address key challenges in current hypertension treatment, according to the UK drugmaker's CEO.

News

Bristol-Myers Squibb's Camzyos has fallen short in a trial in non-obstructive hypertrophic cardiomyopathy, denting its growth prospects.

News

AstraZeneca reveals phase 2b results with its oral PCSK9 inhibitor AZD0780 as it tries to narrow a lead held by MSD with its rival cholesterol drug.

News

Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.

News

Eli Lilly's lepodisiran has been shown to reduce Lp(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial.